|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 205.4 SEK | +0.29% |
|
-1.34% | +61.61% |
Calliditas Therapeutics AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 295.48 million compared to SEK 191.35 million a year ago. Net loss was SEK 246.16 million compared to SEK 187.53 million a year ago.
Basic loss per share from continuing operations was SEK 4.59 compared to SEK 3.49 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +61.61% | 1.05B | |
| +19.36% | 79.99B | |
| +15.93% | 9.25B | |
| +42.06% | 4.45B | |
| -22.01% | 4.43B | |
| +8.28% | 4.03B | |
| +11.22% | 2.24B | |
| -26.61% | 2.18B | |
| +11.64% | 2.02B | |
| -42.69% | 1.79B |
CALLIDITAS THERAPEUTICS AB 